European Society for Radiotherapy and Oncology (ESTRO) shared a post on LinkedIn:
“We are delighted to share that results from the TORPEDO phase III trial have been presented at ICHNO 2026 today by Prof David Thomson and have been published in The Lancet.
This study in oropharyngeal cancer shows that intensity-modulated proton therapy (IMPT) did not improve long-term clinical or patient-reported outcomes compared to IMRT.
These findings reinforce IMRT as the standard of care for oropharyngeal cancer where proton therapy is not routinely used.
At ICHNO 2026, experts have explored how emerging evidence like this is shaping clinical practice in head and neck cancer.”
Other articles about ESTRO on OncoDaily.
